Islet cell transplantation offers a promising avenue for restoring insulin independence in select patients with type 1 diabetes, particularly those with severe hypoglycemia unawareness or labile glycemic control. By infusing donor pancreatic islets into the recipient's liver via the portal vein, the procedure aims to replicate endogenous insulin secretion. However, the long-term success of islet transplantation is significantly challenged by immune-mediated rejection. Understanding the underlying mechanisms, risk factors, and modern management strategies is essential for improving graft survival and patient outcomes.

The Immunobiology of Islet Rejection

Rejection in islet transplantation is a complex, multi-step process driven primarily by the recipient’s adaptive immune system. Unlike solid organ transplants, islets are infused into the hepatic portal system and engraft within the liver sinusoids. This unique microenvironment influences both the immunogenicity and the vulnerability of the graft. The immune response can be categorized into three main phases: hyperacute, acute, and chronic rejection.

Hyperacute Rejection

Hyperacute rejection occurs within minutes to hours after transplantation and is mediated by pre-existing antibodies against donor blood group antigens or major histocompatibility complex (MHC) molecules. Because islet transplantation is performed under ABO blood group compatibility and careful crossmatching, hyperacute rejection is rare in modern practice. Nonetheless, sensitized patients—those with a history of blood transfusions, previous transplants, or pregnancy—remain at elevated risk.

Acute Rejection

Acute rejection typically develops days to weeks after transplantation and involves T-cell–mediated attack on donor islets. Recipient T cells become activated when they recognize donor MHC molecules on antigen-presenting cells (APCs) within the graft or after recipient APCs process and present donor antigens. Activated CD4+ helper T cells release cytokines that recruit CD8+ cytotoxic T cells, natural killer (NK) cells, and macrophages. These effector cells infiltrate the islet graft and cause direct damage, including destruction of beta cells. Without adequate immunosuppression, acute rejection can lead to rapid loss of function.

Chronic Rejection

Chronic rejection is a slow, progressive process that can occur months to years after transplantation. It involves ongoing immune activation, microvascular damage, fibrosis, and eventual loss of islet mass. Unlike acute rejection, chronic rejection may be associated with both T-cell and antibody-mediated mechanisms (e.g., donor-specific antibodies, DSA). Chronic rejection remains a major barrier to long-term graft survival, with only about 50% of patients maintaining insulin independence after five years according to registry data.

Risk Factors for Rejection

Multiple patient- and transplant-related factors influence rejection risk. Identifying and mitigating these risks is a cornerstone of management.

Immunologic Risk Factors

  • HLA (human leukocyte antigen) mismatch: Greater donor-recipient HLA disparity increases the likelihood of T-cell recognition. Complete HLA matching is rarely possible, but minimizing mismatches at key loci (especially HLA-A, -B, -DR) reduces rejection.
  • Pre-existing sensitization: Previous exposure to non-self HLA (via transfusion, pregnancy, or prior transplant) can lead to memory B cells and DSA, which accelerate rejection.
  • Autoimmune history: Because type 1 diabetes is an autoimmune disease, some patients harbor autoreactive T cells that may cross-react with donor islet antigens, contributing to recurrent autoimmunity alongside allorejection.

Procedural and Graft Factors

  • Islet purity and viability: Contaminating exocrine tissue or damaged islets can release proinflammatory factors that amplify immune responses.
  • Implantation site: The liver provides a tolerogenic environment for some cell types, but the portal system exposes islets to first-pass effects of oral immunosuppressants and to high concentrations of gut-derived antigens that might modulate immunity.
  • Number of transplants: Patients receiving multiple islet infusions (serial transplants) accumulate exposure to different donor antigens, raising the risk of sensitization.

Metabolic and Lifestyle Factors

  • Suboptimal glycemic control prior to transplant: Hyperglycemia is proinflammatory and can impair islet function and survival.
  • Obesity and insulin resistance: Increased metabolic demand on the graft may accelerate beta cell exhaustion and contribute to functional loss.
  • Smoking and alcohol use: Both can impair immune regulation and increase microvascular complications that affect graft health.

Clinical Manifestations of Rejection

Detecting rejection early is challenging because islet transplant recipients do not have a palpable graft. Instead, rejection is inferred from metabolic markers and biopsy findings. The most common signs include:

  • Rising blood glucose levels and increasing insulin requirements after a period of stable function.
  • Decline in stimulated C-peptide levels (a marker of endogenous insulin production).
  • Loss of hypoglycemia awareness or recurrence of severe hypoglycemic events.
  • Presence of donor-specific antibodies in the blood.

Liver biopsy with visualization of islet cell clusters (e.g., using special stains for insulin) can confirm rejection but is invasive and not routinely performed. Instead, clinicians rely on a combination of clinical, laboratory, and imaging data.

Managing Rejection: Immunosuppression Strategies

The mainstay of rejection prevention and treatment is immunosuppressive therapy. Over the past two decades, protocols have evolved to balance efficacy against toxicity.

Induction Therapy

Induction agents are given at the time of transplantation to blunt early immune activation. Common agents include:

  • Anti-thymocyte globulin (ATG): Depletes T cells and reduces the number of circulating lymphocytes. ATG is associated with lower acute rejection rates but increases infection risk.
  • Basiliximab: An IL-2 receptor antagonist that blocks T-cell proliferation. It is less potent than ATG but has a favorable side effect profile.
  • Alemtuzumab: A monoclonal antibody that depletes both T cells and B cells. It is used in some centers for particularly high-risk patients.

Maintenance Immunosuppression

Life-long maintenance therapy is required for most islet recipients. The standard regimen combines two or three agents from different classes:

  • Calcineurin inhibitors (tacrolimus, cyclosporine): Block T-cell activation via nuclear factor of activated T-cells (NFAT) inhibition. Tacrolimus is preferred due to greater potency, but it is nephrotoxic and can impair insulin secretion directly (beta-cell toxicity).
  • Antiproliferative agents (mycophenolate mofetil, azathioprine): Inhibit lymphocyte DNA synthesis. Mycophenolate mofetil (MMF) is now standard.
  • Sirolimus (everolimus): An mTOR inhibitor that blocks cytokine-driven T-cell proliferation. Sirolimus has less nephrotoxicity than calcineurin inhibitors but can cause hyperlipidemia, mouth ulcers, and delayed wound healing.

Many modern protocols use a combination of tacrolimus (low dose) with MMF and/or sirolimus to minimize side effects while maintaining efficacy. Some centers also incorporate corticosteroids as part of induction or for acute rejection treatment, but long-term steroid use is avoided due to metabolic side effects.

Treating Acute Rejection Episodes

When rejection is suspected or confirmed, treatment typically involves:

  • Pulse corticosteroids (e.g., methylprednisolone) to rapidly suppress inflammation.
  • Increasing the dose of current immunosuppressants or adding a new agent.
  • In severe or steroid-resistant cases, using ATG or other T-cell depleting antibodies.
  • Monitoring for DSA and considering interventions such as intravenous immunoglobulin (IVIG) or plasmapheresis to reduce antibody-mediated rejection.

Novel and Emerging Strategies to Reduce Rejection

Ongoing research aims to improve graft tolerance and reduce dependence on broad immunosuppression.

Co-Stimulation Blockade

Belatacept, a fusion protein that blocks the CD28-CD80/86 co-stimulation pathway, has shown promise in kidney transplantation and is being explored in islet transplantation. By inhibiting T-cell activation more selectively, belatacept may provide effective rejection prophylaxis with less nephrotoxicity.

Encapsulation and Immune Isolation

Encapsulating donor islets in semipermeable membranes can physically protect them from immune effector cells while allowing glucose and insulin exchange. Several macro- and micro-encapsulation devices are under investigation. Although none are yet clinically approved, early trials show that encapsulated human islets can function for months without systemic immunosuppression, offering a potential breakthrough for rejection avoidance.

Stem Cell–Derived Islets

Induced pluripotent stem cell (iPSC)–derived beta cells from the patient’s own skin or blood would theoretically eliminate the need for immunosuppression. Clinical trials using encapsulated iPSC-derived islets are underway. However, challenges remain, including scalability, consistency of differentiation, and the risk of teratoma formation.

Tolerance Induction

Strategies to induce donor-specific tolerance—where the immune system accepts the graft without ongoing suppression—are a long-term goal. Approaches include:

  • Mixed hematopoietic chimerism via donor bone marrow transplantation combined with islet transplant.
  • Regulatory T cell (Treg) therapy: Expanded recipient Tregs are infused to suppress alloimmune responses.
  • Donor antigen infusion under cover of costimulatory blockade.

Monitoring and Long-Term Care

Regular surveillance is critical for early detection of rejection and for managing complications of immunosuppression.

Blood Biomarkers

  • Fasting glucose, C-peptide, HbA1c: Monitored at every visit to assess metabolic function.
  • Donor-specific antibodies (DSA): Measured quarterly; de novo DSA often precede graft failure.
  • Cytokine panels and serum markers of islet cell injury (e.g., unmethylated insulin DNA) are research tools that may become clinically validated.

Imaging

Imaging of the liver with MRI or ultrasound can sometimes detect graft-related changes, but routine imaging is not standard. One emerging technique is positron emission tomography (PET) with labeled tracers targeting beta cells, which may allow non-invasive visualization of islet mass decline over time.

Preventive Care

Patients on chronic immunosuppression require vaccinations (pneumococcal, influenza, COVID-19, etc.), screening for skin cancers, and management of cardiovascular risk factors. Because calcineurin inhibitors are nephrotoxic, renal function must be monitored, and doses adjusted to prevent end-stage kidney disease. Additionally, the risk of infections—especially cytomegalovirus (CMV), Epstein-Barr virus (EBV), and fungal infections—requires prophylaxis in the early post-transplant period and vigilance thereafter.

Successful management of rejection begins with careful patient selection. Candidates for islet transplantation typically have:

  • Brittle type 1 diabetes with recurrent severe hypoglycemia or hypoglycemia unawareness despite optimal medical therapy.
  • No serious comorbidities such as active infection, malignancy, or significant renal impairment (unless considering simultaneous kidney transplant).
  • Realistic expectations about the risks—including lifelong immunosuppression, possible rejection, and the likelihood of needing multiple islet infusions.

Pretransplant evaluation includes HLA typing and screening for DSA, infectious disease panel, and psychosocial assessment to ensure medication adherence. The decision to proceed with islet transplantation should be made by a multidisciplinary team including endocrinologists, transplant surgeons, immunologists, and nurses.

Outcomes and Prognosis

According to the Collaborative Islet Transplant Registry (CITR), insulin independence rates after one year are approximately 60–80% depending on center experience and protocol. However, many patients require resumption of insulin therapy within two to five years, often due to chronic rejection or loss of islet mass. Rejection is a leading cause of graft failure, but partial function often persists, providing protection against severe hypoglycemia even if insulin is needed. Advances in immunosuppression, especially the adoption of T-cell depleting induction and glucocorticoid-free maintenance, have improved early outcomes. The challenge remains to achieve long-term tolerance and preserve beta cell mass without toxicity.

Future Directions

The next decade promises progress in several areas:

  • Personalized immunosuppression: Pharmacogenomics may help tailor drug selection and dosing to individual metabolic profiles.
  • Bioengineered islets: Scaffolds and microdevices that deliver immunomodulatory molecules may create a local tolerogenic environment.
  • Xenotransplantation: Genetically modified porcine islets that express human complement inhibitors and lack pig MHC could provide an unlimited supply while reducing immunogenicity.
  • Combined cell and gene therapy: For example, using gene editing to knock out HLA expression or to introduce immune-protective factors in donor islets.

Conclusion

Rejection remains the most formidable obstacle to long-term success in islet cell transplantation. A deep understanding of the immune mechanisms, coupled with meticulous patient selection, individualized immunosuppression, and vigilant monitoring, can mitigate many of these risks. While current strategies offer robust protection against acute rejection, chronic rejection and the side effects of immunosuppression continue to limit outcomes. Emerging therapies such as encapsulation, stem cell–derived islets, and tolerance induction hold the potential to transform the field. For now, patients and clinicians must work collaboratively to balance the benefits of improved glycemic stability with the ongoing risks of rejection and treatment toxicity.

For additional information, refer to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) overview on islet transplantation, the American Society of Transplantation’s islet transplant resources, and the Collaborative Islet Transplant Registry (CITR) public reports.